HAYA Therapeutics

HAYA Therapeutics is an innovative biotechnology company focused on developing next-generation therapies for fibrotic diseases. The company operates in the biopharmaceutical sector, targeting conditions such as heart failure, lung fibrosis, kidney fibrosis, liver fibrosis, and fibrotic processes in solid tumor cancers. HAYA Therapeutics leverages its proprietary discovery engine to identify long non-coding RNAs (lncRNAs) that play a crucial role in tissue and cell-specific fibrosis. Their lead therapeutic candidate is an antisense molecule targeting Wisper, a cardiac-enriched master driver of fibrosis, which has shown promising results in preclinical testing by halting and potentially reversing heart failure-related fibrotic processes. The company's business model revolves around research and development, aiming to bring safe, effective, and accessible anti-fibrotic therapies to market. Revenue generation is expected through the commercialization of these therapies, either independently or through strategic partnerships with larger pharmaceutical companies. HAYA Therapeutics serves patients suffering from fibrotic diseases and collaborates with healthcare providers and research institutions. The company is headquartered at the Biopole Science Park in Lausanne, Switzerland, and is actively expanding its team to support its growth and innovation efforts.

Keywords: biotechnology, fibrotic diseases, lncRNA, antisense molecule, heart failure, lung fibrosis, kidney fibrosis, liver fibrosis, solid tumor cancers, Biopole Science Park.